Literature DB >> 32006340

SEOM clinical guideline thyroid cancer (2019).

E Gallardo1, J Medina2, J C Sánchez3, A Viúdez4, E Grande5, I Porras6, T Ramón Y Cajal7, J Trigo8, L Iglesias9, J Capdevila10.   

Abstract

Thyroid carcinoma is the most frequent endocrine malignancy and accounts for around 3% of global cancer incidence. Different histologies and clinical scenarios make necessary a multidisciplinary approach that includes new diagnostic methods and surgical, radiopharmaceutical and systemic therapies. This guideline updates several aspects of management of thyroid cancer.

Entities:  

Keywords:  Multidisciplinary; Systemic therapy; Thyroid cancer

Mesh：

Year:  2020        PMID： 32006340     DOI： 10.1007/s12094-019-02284-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  41 in total

1.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.

Authors:  C A Dykewicz
Journal:  Clin Infect Dis       Date:  2001-06-14       Impact factor: 9.079

2.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

3.  Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis.

Authors:  Salvatore Vaccarella; Silvia Franceschi; Freddie Bray; Christopher P Wild; Martyn Plummer; Luigino Dal Maso
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

4.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

Review 5.  Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan.

Authors:  Iwao Sugitani; Naoyoshi Onoda; Ken-Ichi Ito; Shinichi Suzuki
Journal:  J Nippon Med Sch       Date:  2018       Impact factor: 0.920

6.  Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach.

Authors:  Marco Volante; Paola Collini; Yuri E Nikiforov; Atsuhiko Sakamoto; Kennichi Kakudo; Ryohei Katoh; Ricardo V Lloyd; Virginia A LiVolsi; Mauro Papotti; Manuel Sobrinho-Simoes; Gianni Bussolati; Juan Rosai
Journal:  Am J Surg Pathol       Date:  2007-08       Impact factor: 6.394

7.  18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.

Authors:  Trond Velde Bogsrud; Dimitrios Karantanis; Mark A Nathan; Brian P Mullan; Gregory A Wiseman; Jan L Kasperbauer; Carl C Reading; Ian D Hay; Val J Lowe
Journal:  Thyroid       Date:  2008-07       Impact factor: 6.568

8.  Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Authors:  Vivek Subbiah; Robert J Kreitman; Zev A Wainberg; Jae Yong Cho; Jan H M Schellens; Jean Charles Soria; Patrick Y Wen; Christoph Zielinski; Maria E Cabanillas; Gladys Urbanowitz; Bijoyesh Mookerjee; Dazhe Wang; Fatima Rangwala; Bhumsuk Keam
Journal:  J Clin Oncol       Date:  2017-10-26       Impact factor: 44.544

Review 9.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.

Authors:  J Ferlay; M Colombet; I Soerjomataram; T Dyba; G Randi; M Bettio; A Gavin; O Visser; F Bray
Journal:  Eur J Cancer       Date:  2018-08-09       Impact factor: 9.162

10.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Authors:  Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544
View more
  8 in total

1.  2019 SEOM guidelines (the end of a decade).

Authors:  A González-Del-Alba; Á Rodríguez-Lescure
Journal:  Clin Transl Oncol       Date:  2020-02-06       Impact factor: 3.405

2.  A Mathematical Model to Assess the Effect of Residual Positive Lymph Nodes on the Survival of Patients With Papillary Thyroid Microcarcinoma.

Authors:  Wen Liu; Xuejing Yan; Zhizhong Dong; Yanjun Su; Yunhai Ma; Jianming Zhang; Chang Diao; Jun Qian; Tao Ran; Ruochuan Cheng
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 3.  The active surveillance management approach for patients with low risk papillary thyroid microcarcinomas: is China ready?

Authors:  Wen Liu; Xuejing Yan; Ruochuan Cheng
Journal:  Cancer Biol Med       Date:  2021-09-24       Impact factor: 5.347

4.  Association between functional polymorphisms in the flanking region of miR-143/145 and risk of papillary thyroid carcinoma: A case-control study.

Authors:  Yichao Wang; Shengliang Zhou; Wanjun Zhao; Zhihui Li; Jingqiang Zhu; Tao Wei; Haolan Song
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.889

Review 5.  Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.

Authors:  María San Román Gil; Javier Pozas; Javier Molina-Cerrillo; Joaquín Gómez; Héctor Pian; Miguel Pozas; Alfredo Carrato; Enrique Grande; Teresa Alonso-Gordoa
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  Circ_0000144 acts as a miR-1178-3p decoy to promote cell malignancy and angiogenesis by increasing YWHAH expression in papillary thyroid cancer.

Authors:  Yinli Ma; Dan Yang; Pingan Guo
Journal:  J Otolaryngol Head Neck Surg       Date:  2022-07-28

7.  Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study.

Authors:  Juan Antonio Vallejo Casas; Marcel Sambo; Carlos López López; Manuel Durán-Poveda; Julio Rodríguez-Villanueva García; Rita Joana Santos; Marta Llanos; Elena Navarro-González; Javier Aller; Virginia Pubul; Sonsoles Guadalix; Guillermo Crespo; Cintia González; Carles Zafón; Miguel Navarro; Javier Santamaría-Sandi; Ángel Segura; Pablo Gajate; Marcelino Gómez-Balaguer; Javier Valdivia; Manel Puig-Domingo; Juan Carlos Galofré; Beatriz Castelo; María José Villanueva; Iñaki Argüelles; Lorenzo Orcajo-Rincón
Journal:  Eur Thyroid J       Date:  2022-08-11

8.  Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.

Authors:  Hiroshi Imaoka; Masafumi Ikeda; Kosuke Maehara; Kumiko Umemoto; Masato Ozaka; Satoshi Kobayashi; Takeshi Terashima; Hiroto Inoue; Chihiro Sakaguchi; Kunihiro Tsuji; Kazuhiko Shioji; Keiya Okamura; Yasuyuki Kawamoto; Rei Suzuki; Hirofumi Shirakawa; Hiroaki Nagano; Makoto Ueno; Chigusa Morizane; Junji Furuse
Journal:  BMC Cancer       Date:  2020-10-01       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.